Aus, G.

cancer prostate prostate cancer screening biopsy study group treatment patient death erspc velocity european follow-up antigen result european randomized study psa velocity mortality analysis rp group outcome urology value gleason diagnosis randomized number surveillance score rotterdam cohort university therapy roobol contamination control management prostate biopsy model survival screening group centre control group psa level disease sweden trial characteristic cause center roobol mj table psa measurements analyses effect prostate-speci fic antigen european randomised study level van den bergh schr öder fh measurement control arm department prostate-speci difference schroder netherland finland prostate-specific biopsied screening-positive nonattendance randomised accuracy erasmus university gleason score psa dt screening-positive men reduction